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ABSTRACT
The plasma of patients with hepatitis C contains chromosome-damaging substances, 
the so-called “clastogenic factors” (CFs), as this is the case for other chronic inflam-
matory diseases and after radiation exposure. These endogenous clastogens, formed 
as a consequence of increased superoxide production by inflammatory cells, can be 
detected with cytogenetic methods, as they are used for exogenous clastogens. The 
long-lived, autosustained DNA-damaging effects of CFs are risk factors for the develop-
ment of cancer and leukemia. In hepatitis C, the highest clastogenic scores has been 
observed in patients with hepatocellular carcinoma. In agreement with the link to 
inflammation, clastogenic score are correlated with necro-inflammatory scores in 
liver biopsies. Antioxidant therapy with a powerful superoxide scavenger resulted in 
normalization of clastogenic scores and significant decreases in aminotransferase lev-
els, but did not influence the virus load. Preliminary results of our study on a limited 
number of patients suggest that pre-treatment with antioxidants may improve the 
outcome of interferon/ribavirin treatment. A comparison of a three-month treatment 
with either interferon alone or the antioxidant alone, yielded similar results for re-
duction of ALT levels, but only complete normalization of clastogenic scores for the 
antioxidant. Further studies have to be conducted to see whether a combination of 
an antiviral agent with an appropriate antioxidant would allow to reduce interferon 
and its side effects.Combination of antioxidants with IFN/RIBA was also reported by 
other authors with discordant results. The CF-test can be useful in clinical trials for the 
choice of the appropriate antioxidant.
ARTICLE INFO
Article history:
Received: 04 Jan 2011
Revised: 11 Feb 2011
Accepted: 01 Apr 2011
Keywords:
Hepatitis C virus
Oxidative stress
Cytogenetic
Article Type:
Review Article
  c 2011 Kowsar M.P.Co. All rights reserved.
  Implication for health policy/practice/research/medical education: 
The fact that DNA damage induced during chronic hepatitis C may be reduced by antioxidants is of importance for prevention of 
hepatocellular carcinomas. The CF-test is an appropriate and easy tool to follow chromosome mutation in the disease process.
  Please cite this paper as: 
Emerit I. Cytogenetic methods for detection of oxidative stress and evaluation of antioxidant therapy in hepatitis C infection. Hepat 
Mon. 2011;11(6):434-9.
 Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
1. Introduction
Oxidative stress is involved in chronic hepatitis C, and 
efforts have been made to influence the disease process 
with antioxidants (1-3). Oxidative damage has been docu-
mented in lipids, proteins and DNA. Increased oxyradical 
production could be detected on liver biopsies by direct 
measurements with spin trapping (4). High resting lev-
els of superoxide anion in the whole blood of patients 
were detected with chemiluminescence techniques (5). 
We have reported previously that clastogenic (i.e., chro-
mosome  damaging)  substances,  the  so-called  clasto-
genic factors (CFs), are present in the plasma of patients 
with hepatitis C (6), as this is the case for a variety of Hepat Mon. 2011;11(6):434-439
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other  pathological  conditions  accompanied  by  oxida-
tive stress. These include irradiation exposure, chronic 
inflammatory  diseases,  HIV  infection,  ischemia  reper-
fusion  injury,  the  hereditary  chromosomal  instability 
syndromes and others (7). The formation, as well as the 
chromosome damaging effects of CFs, is mediated by the 
superoxide anion radical since they are regularly inhib-
ited by superoxide dismutase (SOD) or other superoxide 
scavengers. For this reason, the term “superoxide-medi-
ated clastogenesis” has been proposed (8). Superoxide 
is not a direct DNA-damaging agent, but an initiator of 
a series of events leading to the formation of clastogenic 
materials. Biochemical analysis has identified lipid per-
oxidation  products,  arachidonic  acid  metabolites,  nu-
cleotides of inosine and cytokines, in particular tumor 
necrosis factor (TNF) alpha, as the clastogenic and also 
superoxide stimulating components of CFs. Due to their 
chromosome-damaging  properties,  these  substances 
can be detected with classical cytogenetic methods.
2. Formation and action of CF
When cell cultures are exposed to superoxide-generat-
ing systems, such as a xanthine-xanthine oxidase reaction 
or a respiratory burst stimulated by a tumor promoter, 
mitotic cells show chromosomal breakage, and the super-
natant of these cultures induces breakage, when trans-
ferred to other cell cultures. This could be consistently 
prevented by SOD. Exposure of cell-free culture medium 
or serum does not result in clastogenic activity, indicat-
ing that CFs are cellular products. After resuspension of 
the cells in fresh medium, they continue to release CFs 
in absence of the superoxide generating system. Similar 
to the events observed in cell culture under experimen-
tal conditions, CF formation can occur in the organisms 
during  inflammatory  diseases  via  a  respiratory  burst 
by competent cells. After activation of phospholipase A, 
arachidonic acid (AA)-derived eicosanoids are released 
from cellular membranes and further degraded to the 
breakdown product 4-hydroxynonenal (HNE), which is 
highly clastogenic at 0.1 µM concentration. This pathway 
of CF formation can be blocked not only by dismutation 
of the initiating superoxide by SOD, but also by inhibi-
tors of the AA cascade. In culture systems, the formation 
of HNE needs a minimum of 18 hours, without further 
increase after 24 hours. SOD or other inhibitors of CF for-
mation are most efficient, if added to the cultures dur-
ing the first 24 hours of the cultivation period, i.e., before 
accumulation of HNE. This aldehyde has no superoxide 
generating properties, but is responsible for DNA dam-
age by inactivation of functional SH groups of DNA poly-
merases and adduct formation with cellular thiols.
Superoxide generation via a respiratory burst also acti-
vates another enzyme—protein kinase C. This leads to re-
lease of TNF-α, the clastogenic properties of which could 
be confirmed by the study of the commercial product. 
The presence of TNF in CFs leads to further superoxide 
generation and amplifies the process. Chronic inflam-
mation is also accompanied by increases in adenosine 
deaminise and xanthine oxidase. This leads to nucleotide 
pool imbalances with formation of inosine tri- and di-
phosphate, not produced in the organism under normal 
conditions. These nucleotides are not only clastogenic, 
but have also superoxide stimulating properties, as dem-
onstrated with chemiluminescence or the cytochrome 
C reduction assay. Amplification of CF formation is the 
consequence, as mentioned above for TNF-α. In addition, 
ITP raises intracellular calcium levels, activates lysosom-
al enzymes and induces chromosomal damage through 
the action of nucleases. Competition between ITP and 
ATP-binding  sites  of  DNA-polymerases  may  also  affect 
DNA repair. We may deduce that CF formation as well as 
CF action is multifactorial and multistep processes, re-
sponsible for an autosustained DNA damaging process 
(7).
As in other chronic inflammatory diseases, these mech-
anisms of CF formation and action are implicated in pa-
tients with hepatitis C. Monocytes of HCV-infected per-
sons are in an activated state and represent a source of 
superoxide for CF formation (9). The Kupffer cells of the 
liver represent the largest population of macrophages in 
the human body. They release various mediators includ-
ing superoxide, eiosanoids, and cytokines. TNF-α is pro-
duced in excess in chronic hepatitis (10). Increased lev-
els of xanthine oxidase, coupled with an increase in the 
substrates xanthine and xanthine oxidase were noted in 
virus-infected tissues (11). The xanthine oxidase reaction 
may therefore be another source of superoxide in hepati-
tis C. Also the enzyme adenosine deaminise was found to 
be increased in patients with viral hepatitis (12) leading 
to ITP formation, as described above. Since it was shown 
that lipid peroxidation products are increased in plasma 
(13) and liver of patients (14), the clastogenic degradation 
product HNE should be present also. The fact that CFs of 
hepatitis C patients were detected in the same low mo-
lecular weight fraction as CFs of other origin, as well as 
the anticlastogenic effects of SOD are arguments for sim-
ilarities in their composition. Clastogenic action of HCV 
can be excluded, given the pore size of the ultrafiltration 
system retentive for viruses.
 
3. Measurement of clastogenic activity: The 
CF test
CFs are endogenous clastogens, and the methods for 
their detection follow the protocols established for the 
study of chromosomal breakage after exposure to exog-
enous clastogens. Regular blood cultures set up with 0.5 
mL of blood from a healthy donor are exposed to plasma 
or plasma ultrafiltrates from patients. Ultrafiltrates are 
preferable,  since  the  ultrafiltration  step  eliminates  all 
high molecular weight materials, which might disturb 
culture growth in case of blood group incompatibilities. 
Also residual cells in patients' plasma are retained by the 
filter. Since the clastogenic activity is in the small molec-Hepat Mon. 2011;11(6):434-439
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ular weight fraction, the plasma is filtered through Milli-
pore ultrafiltration filters with a cutoff at 30,000 Daltons. 
The ultrafiltrates are unstable at room temperature and 
loose also their activity in the refrigerator overnight. Fro-
zen, they can be conserved over years. In order to avoid 
repeated freezing and thawing, aliquots of the samples 
should be prepared. The clastogenic activity is not lost 
during lyophilization, if done rapidly in small aliquots.
The culture medium has to be poor in free radical scav-
engers. TCM 199 or RPMI 1640 mL (5 mL per culture tube) 
are recommended, while RPMI 1629 or Ham's FT are not 
convenient because of their high L-cysteine content. The 
medium  is  supplemented  with  fetal  calf  serum  (1  mL 
per culture). It should have a yellow aspect indicating 
that there was no hemolysis during serum preparation. 
Otherwise SOD from lysed erythrocytes can be present at 
anticlastogenic quantities. Bovine serum may be rich in 
vitamin E and inhibit clastogenesis related to lipid per-
oxidation. The usual quantity of ultrafiltrate varies be-
tween 100 and 200 µL for a total of 5 mL medium plus 1 
mL serum per culture. Higher doses may have cytotoxic 
effects resulting in “false negative results.” The CF test can 
be done only on well proliferating cultures, and there-
fore the test has to be repeated with lower doses. On the 
other hand, if 100 µL do not induce breakage, the culture 
has to be repeated with a higher dose. If possible, both 
quantities should be tested simultaneously. Addition of 
CF at the beginning of the cultivation period yields the 
highest aberration rates. This is explained by the multi-
factorial, multistep process of CF action with amplifica-
tion of the initial clastogenic activity.
Lymphocyte proliferation is stimulated by the addition 
of phytohemagglutinin. After 48 or 72 hr of incubation 
at 37 °C, the mitoses are arrested in metaphase by the ad-
dition of colchicine, 2 hr before harvesting. The mitosis 
rate is in general higher at 72 hr, but 48 hr cultures are 
preferable,  if  the  nature  of  chromosomal  aberrations 
and not only breaks are evaluated. Microscopic slides are 
prepared according to classical cytogenetic procedures. 
The tubes are centrifuged at low speed (800-1000 t) for 
10 min. The pellet is suspended in 10 mL of hypotonic 
KCl (0.28%–0.4%) for 20 min at 37 °C. After centrifugation, 
the cells are fixed in alcohol-acetic acid (3:1). Two to three 
changes are necessary until the supernatant does no lon-
ger show traces of hemoglobin. After the last change, the 
pellet is suspended in several drops of ice-cold glacial 
acetic acid, spread on cold wet slides and dried at room 
temperature or with a hair dryer. Good spreading is only 
obtained on absolutely clean slides, on which the drop is 
not retracting. The chromosomes are stained with Giem-
sa, and 50 well-spread metaphase plates are examined 
on coded slides for the presence of chromatid type aber-
rations (chromatid and isochromatid breaks, telomeric 
extrusions or acentric fragments). Gaps are not consid-
ered as aberrations. Chromosome type aberrations such 
as  rings,  dicentrics  or  other  structurally  rearranged 
chromosomes are rarely observed. This is typical for CF-
induced chromosomal breakage and due to the multifac-
torial process of break induction.
A series of samples is tested the same day on the cul-
tures set up with the same donor blood. One or two ad-
ditional cultures are set up without ultrafiltrate as con-
trols. The background level of aberrations in the control 
is deduced from the aberration rate in the ultrafiltrate-
treated cultures. The difference of the two values is called 
the  adjusted  clastogenic  score  (ACS).  The  background 
level of the control culture should not exceed 2%. Donors 
exhibiting increased chromosomal breakage for other 
reasons, i.e. exposure to x-ray procedures, are not suit-
able for the CF-test. Ultrafiltrates prepared from blood of 
healthy adults are not clastogenic, as ascertained in our 
laboratory by the study of 100 samples. Only five of these 
samples  induced  three  additional  aberrations  for  100 
mitoses studied (ACS + 3, or 6%). The others induced one 
or two aberrations or no aberrations at all. According to 
these data, ACS + 4 (8%) or higher are CF+. The Mean ± SD 
ACS for the 100 studied samples was 0.8% ± 1.0%. In an-
other series of out-patients consulting for various other 
health problems, (called “sick controls”), the Mean ± SD 
value was higher (3.3% ± 2.1%).
Since chromosome type aberrations are rare, the ob-
server may score only open breaks of one or both chro-
matids or acentric fragments. They do not need cytoge-
netic training therefore. The study of sister chromatid 
exchanges may be proposed, instead. However, compara-
tive studies have shown that break events are 3–5 times 
more frequent in CF-treated cultures compared to con-
trols, while SCEs, though regularly increased, are gener-
ally not even doubled. Fibroblasts, endothelial or meso-
thelial cells of human origin or from other species may 
be used for the CF test instead of blood, but the breakage 
rates are lower. This is due to the presence of monocytes 
in the blood cultures, which are responsible for the above 
mentioned amplification process. The dividing lympho-
cytes  are  the  indicators  of  the  damage.  For  the  same 
reason, cultures set up with pure lymphocytes are not 
appropriate. CFs do not induce lesions in isolated DNA. 
They can be studied only on cellular systems because of 
the indirect action mechanism of break induction.
The concentration of each of the clastogenic compo-
nents may not reach detectable levels in biochemical as-
says. The clastogenic action is the result of the synergistic 
action of all CF components. Therefore the cytogenetic 
assay is more sensitive. Since the clastogenic activity in 
patients’ plasma induces also chromosomal breakage in 
their own cells, cytogenetic studies can be done also on 
patients’ blood cultures. However, these studies have to 
be conducted on freshly drawn blood, while the study of 
CF in the plasma can be done on frozen ultrafiltrates af-
ter accumulation of samples.
 
4. Results obtained with the CF-test in pa-
tients with chronic hepatitis C
In  confirmation  of  our  previous  findings  in  other Hepat Mon. 2011;11(6):434-439
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chronic inflammatory diseases, patients with hepatitis C 
exhibit increased chromosomal breakage, and their plas-
ma exerts clastogenic effects in blood cultures of healthy 
donors. In a first series of 20 patients (6), the Mean ± SD 
ACS was 9.30% ± 2.85%, while that of the 20 healthy con-
trols was 1.1% ± 2.4% (p < 0.001). No clastogenic effects 
were produced, if the test cultures received simultane-
ously SOD. In 19 patients, the ACS was 8% or higher, i.e. 
95% of patients were CF+ (range: 8%–14%). The patients 
were treated with interferon (IFN-α, three times a week 
at a dose of 5 MU). After three months, only three of 20 
studied patients were still CF+. The Mean ± SD ACS was 
reduced to 3.8% ± 3.3%. This is still increased compared to 
healthy controls, but near the values observed in “sick 
controls” (3.3% ± 2.1%). After discontinuation of the treat-
ment at 12 months, the ACS values were in the same range 
and remained constant during the six months of follow-
up. Alanine aminotransferase (ALT) levels were increased 
in all patients and decreased progressively under treat-
ment from a Mean ± SD level of 100 ± 70 IU/L before the 
treatment to 80 ± 80 IU/Lt three months, 70 ± 43 IU/L at 
12 months. ALT remained stable until the end of the six 
months of follow-up (70 ± 4 2 IU/L). There was no corre-
lation between ALT level and ACS for individual results. 
However, when groups were formed, the group of nine 
patients with normalized ACS (3.11% ± 1.4%) had also nor-
malized ALT levels (33.1 ± 8.31 IU/L). In agreement with the 
link to inflammation, ACS was correlated with necroin-
flammatory scores in liver biopsies. However, viral load 
and ACS were not correlated. If persistence of normal 
results for ALT and absence of detectable replicating vi-
rus six months after discontinuation of the treatment is 
conventionally defined as a “sustained response,” five of 
the 20 patients treated with INF-α were responders (SR), 
11 were non-responders (NR) and four developed relapse 
(RR). The mean ACS scores were lower in SR than in NR 
and RR.
Another  series  of  patients  received  ribavirin  and  pe-
gylated interferon alpha 2B (PEG-IFN/RIBA) as a conven-
tional antiviral treatment over a period of 12 months and 
were followed for six months (15). This treatment was 
started after a pre-treatment with an antioxidant during 
three months. Since we knew from our in vitro results 
with SOD that the clastogenic effect of CF is related to su-
peroxide production, we choose a product known for its 
strong  superoxide-scavenging  activity,  the  antioxidant 
Biofactor AOB (AOA Co. Kobe, Japan). AOB is a processed 
grain food, extracted from various plants according to 
a patented procedure, during which fermentation with 
Aspergillus orizae plays a role for the bioavailability of the 
active compounds, in particular flavonoids and phenols. 
The flavonoid rutin is present at high concentrations (33 
mg/100 g). Other major components are the isoflavons 
daidz(e)in and genest(e)in. AOB contains also vitamins 
and various trace elements with antioxidant properties, 
but at very low concentrations. AOB was compared to a 
placebo, extracted from other plants, but of similar as-
pect and very low superoxide-scavenging capacity. For 
the same inhibitory effect on superoxide production by 
a xanthine-xanthine oxidase reaction, 4.5 mg/mL of the 
placebo were needed for only 0.0113 mg/mL AOB. In agree-
ment herewith, the placebo did not significantly reduce 
the ACS during the three-month treatment. On the op-
posite, AOB was highly anticlastogenic and reduced ACS 
from a Mean ± SD of 12.4% ± 1.8% to 3.7% ± 3.3% (p < 0.001). 
ACS  further  decreased  during  the  following  months 
to normal values for healthy adults (1.8% ± 1.6%) despite 
discontinuation of AOB. Significant decreases were also 
observed for aminotransferase levels in the AOB group, 
but not in the placebo group. Mean values for HCV-RNA, 
however, remained unchanged in both groups.
When the antiviral treatment started, the AOB-pre-treat-
ed group had normalized ACS (1.8% ± 1.6%), while the pla-
cebo pre-treated group had highly increased ACS (10.6% ± 
4.6%; p < 0.0001). Thus both groups differed with respect 
to oxidative stress and chromosomal breakage. Also, the 
mean aminotransferase levels were lower compared to 
the placebo-pre-treated group (104.8 IU for ALT and 44.0 
IU for AST compared to 147.0 and 74.6 IU, respectively). 
Six months after discontinuation of the 12-month antivi-
ral therapy, a sustained response was observed in five of 
nine patients pre-treated with AOB, while the seven pa-
tients pre-treated with placebo were all non-responders. 
One may ask, whether the more favorable outcome of 
PEG-IFN/RIBA treatment for the group pre-treated with 
AOB was related to the better conditions at the start due 
to the antioxidant therapy.
5.  Clastogenic  factors  and  hepatocellular 
carcinoma
When the HCV-infected patients were compared among 
each other, the mean values and percentages of CF-posi-
tive samples were higher for patients with cirrhosis and 
hepatocellular carcinoma compared to patients without 
these complications (11.1% ± 2.7%, 11.1% ± 4.0% and 0.8% ± 
4.4%, respectively) (16). The differences are not statisti-
cally significant, probably because of the small number 
of participants and the high standard deviation. If the 
number of CF + patients was compared instead of mean 
ACS, 34 of the 40 hepatitis C patients without complica-
tions were CF + (85%) compared to 16 of 17 patients (94%) 
with liver cirrhosis and 16 of 17 patients (94%) with hepa-
tocellular carcinoma. For 10 of the 17 hepatoma samples, 
the culture failed with the usual dose of 200 µL ultrafil-
trate and had to be repeated with 100 µL. Despite the re-
duced volume of clastogen, the ACS were highest in these 
10 cultures (12.6% ± 4.2%), while the ACS in the seven other 
cultures exposed to 200 µL were similar to those of pa-
tients with liver cirrhosis (11.1% ± 4.0% and 11.1% ± 2.7%, re-
spectively). The patients with hepatocellular carcinoma 
were compared to a group of patients with liver metas-
tases from other malignancies. Of whom 45% were CF + 
with a Mean ± SD ACS of 8.7 ± 4.3, tested with the usual 
quantity of 200 µL. If these patients were tested with 100 
µL in comparison to the hepatoma patients, the differ-Hepat Mon. 2011;11(6):434-439
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ences in ACS were significant (3.6% ± 3.2% and 12.6% ± 4.2%, 
respectively). Among the 11 patients with metastatic liver 
disease, only one was CF + in contrast to all 10 patients 
with hepatoma. High clastogenic activity observed with 
100 µL plasma ultrafiltrate after culture failure with the 
usual dose of 200 µL suggests HCV-positive hepatoma.
6. Clastogenic factors and carcinogenesis
Radiobiologists introduced the term “clastogenic plas-
ma factor” in the early 1970s. They already proposed that 
they were responsible for late effects of radiation such as 
cancer and leukemia in irradiated subjects (17). In more 
recent years, the generation of biologically active, diffus-
ible products by exposure to alpha particles has been 
considered as a possible mechanism for radon-induced 
carcinogenesis in the respiratory tract (18). The strongest 
evidence for the involvement of chromosome mutation 
in carcinogenesis came from the cytogenetic studies of 
the so-called “chromosome breakage syndromes,” rare 
hereditary disorders associated with the highest cancer 
incidence in humans (19). Previous studies of our labo-
ratory indicate that CFs are regularly produced in a va-
riety of pathologic conditions accompanied by chronic 
inflammation, oxidative stress and CF formation (20). In 
Crohn’s disease, the risk of colorectal cancer is 20 times 
greater than in the general population (21). Also, among 
the connective tissue diseases, the cancer risk is consid-
ered to be increased. In patients with progressive system-
ic sclerosis, lung and esophagus cancer occur on the basis 
of sclerotic fibrosis (22). In association with dermatomy-
ositis, a wide variety of tumors has been observed (23), 
while the malignancies observed in Sjogrens’s syndrome 
are almost exclusively lymphoreticular in type (24). This 
seems to be the case also in patients with rheumatoid 
arthritis, periarteritis nodosa and lupus erythematosus. 
The data on lupus erythematosus are summarized in a 
Finnish  study  (25),  confirming  previous  reports  of  in-
creased cancer incidence in these patients. A correlation 
between increased chromosomal breakage, the presence 
of CFs in the plasma, and a high frequency of tumors was 
also documented in an animal model for lupus erythe-
matosus in the New Zealand Black (NZB) mouse (26). By 
selective matings according to chromosomal breakage 
frequencies in bone marrow cells, it was possible to de-
velop two NZB sublines—a high-breakage (HB) and a low-
breakage (LB) line. At the age of 18 months, the frequency 
of tumors was four times higher in HB than in LB mice. 
There was a significant difference for CF activity in the 
plasma and for spontaneous superoxide production by 
peritoneal macrophages from these mice. The HB and LB 
lines differed also significantly in retrovirus production. 
It has been shown that extracellular superoxide genera-
tion activates proto-oncogenes and induces mutations 
at tumor suppressor loci (27). The genomic instability 
increases the chance that mutation(s) required for neo-
plastic  transformation  would  occur  (1).  Chromosomal 
breakage visible under the microscope is an indicator 
for events occurring in DNA. It demonstrates that the an-
tioxidant defences and the DNA repair system are over-
whelmed. As mentioned above, certain components of 
CF have not only superoxide-stimulating properties, but 
are also interfering with DNA repair enzymes. The path-
way of carcinogenesis via CF formation appears to be of 
particular interest because superoxide scavengers can be 
used as anticarcinogens. CF-induced DNA damage may 
be responsible also for the high risk of liver cancer in 
patients with hepatitis C. The detection of CFs indicates 
that the chromosomal damage in patients’ cells is not 
transient, but that the person will be exposed to clasto-
genic effects as long as the vicious circle of CF formation 
via superoxide and stimulation of more superoxide by 
CF is not interrupted.
7. Conclusion
The CF-test is a sensitive assay for the detection of oxida-
tive stress in hepatitis C. At the same time, this test dem-
onstrates the occurrence of damage to DNA, a risk factor 
for the development of cirrhosis and hepatocellular car-
cinoma. Clastogenic effects correlate with necroinflam-
matory activity in the liver and can be an indicator for 
the need of a liver biopsy. In clinical trials, the test can be 
useful for the choice of an antioxidant for complementa-
ry treatment. Larger series of patients have to be studied 
combining antioxidant with antiviral treatment. 
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